Los Angeles TimesStem cell scientist to become the latest Democrat trying to topple Dana Rohrabacher in OC House raceLos Angeles TimesAn internationally known stem cell scientist and entrepreneur will join the ranks of candidates trying to unseat Repub… Continue reading
Twist Bioscience and the BioBricks Foundation Announce First-of-its-Kind Partnership to Provide 10000 Public-Benefit …PR Newswire (press release)We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a high … Continue reading
Spectrum News |
New Law Opens Door for Stem Cell Therapy in Texas
Spectrum News “This is going to protect patient health, and provide for the treatments to be done here locally at home,” said Mike Byrom, the Chief Science Officer at Austin stem cell bank BioEden. Byrom said the new law will keep patients in the country, and will … |
KING5.com |
Cancer immunotherapy used to treat blood cancer | KING5.com
KING5.com The re-engineering of a person’s car T cells to fight cancer in their body has become a promising tool for forms of blood cancer. Researchers and doctors hope it … |
Healthline |
Is Human Embryonic Stem Cell Research in Jeopardy?
Healthline In 2010, when renowned stem cell scientist Lawrence Goldstein, PhD, published his groundbreaking book “Stem Cells for Dummies,” with co-author Meg Schneider, the forecast for human embryonic stem cell research had just begun to brighten. In 2001 … A New Generation of Stem Cell Therapy Launches To The PublicDigital Journal |
Healthline |
Is Human Embryonic Stem Cell Research in Jeopardy?
Healthline In 2010, when renowned stem cell scientist Lawrence Goldstein, PhD, published his groundbreaking book “Stem Cells for Dummies,” with co-author Meg Schneider, the forecast for human embryonic stem cell research had just begun to brighten. In 2001 … A New Generation of Stem Cell Therapy Launches To The PublicDigital Journal |
|
Gene therapy by the numbers
BioPharma Dive Gene therapies have been in clinical development for decades, a winding, stop-and-start path toward transforming science’s understanding of the genome into commercial therapies. Strimvelis, a gene therapy made by the British pharma GlaxoSmithKline and … |
|
Alternative pricing models a fantasy for gene therapies?
BioPharma Dive Once upon a time, gene therapy was thought to be the miracle of science that was going to change everything. After safety issues and patient deaths, that didn’t work out quite like the industry had hoped. Yet, 20 years later, the next generation of … |